Ronac Mamtani, MD, MSCE
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858
Penn Medicine Provider

About me

  • Section Chief, Genitourinary Cancers, Hematology-Oncology
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: State University of New York at Stony Brook
  • Residency: NewYork-Presbyterian/Weill Cornell Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

190 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
efficient
October 2025
he is an excellent doctor
October 2025
he takes this time to talk to me about what's going on and i really appreciate that and he answers all my questions
October 2025
he is the best

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Mamtani is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U. Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2 , J Comp Eff Res: 2025

Chow RD, Mamtani R. Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma , Urol Oncol, 43(10): 2025,597

Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R. Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States , J Med Econ: 2025

Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R. Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis , J Manag Care Spec Pharm: 2025

Chow RD, Mamtani R. Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma , Clin Genitourin Cancer: 2025

Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R. Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies , JAMA Netw Open, 8(7): 2025,e2520726

Lian Y, Voruganti T, Lu J, Long Q, Mamtani R. Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates , JAMA Netw Open, 8(7): 2025,e2519524

Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R. Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer , J Natl Cancer Inst, 117(6): 2025,1276-1278

Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA. Adoption of Broad Genomic Profiling in Patients With Cancer , JAMA Oncol, 11(6): 2025,666-668

Barsouk AA, Yang A, Sussman JH, Elghawy O, Xu J, Xu J, Meng L, Koga S, Du W, Mamtani R, Mei L. Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis , Clin Genitourin Cancer, 23(5): 2025,102395